Azenta, Inc. (AZTA) AI Stock Analysis

Azenta, Inc. offers comprehensive life science sample exploration and management solutions to the global life sciences market across North America, Europe, China, and the Asia Pacific. The company operates through two segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products segment supplies automated cold sample management systems, sample preparation and handling equipment, consumables, and instruments. The Life Sciences Services segment provides sample management programs, integrated cold chain solutions, informatics, sample storage, genomic sequencing, gene synthesis, laboratory analysis, and biospecimen procurement. Formerly known as Brooks Automation, Inc., Azenta supports pharmaceutical companies, biotechnology firms, biorepositories, and research institutes.

Azenta reported revenue of $513.7M in FY2021, growing 32.2% year-over-year, before reaching $555.5M in FY2022 and $665.1M in FY2023. Revenue fell 13.8% in FY2024 to $573.4M and increased 3.6% in FY2025 to $593.8M, representing a 5-year revenue CAGR of 8.9%. Gross margin expanded from 41.8% in FY2021 to 45.5% in FY2025, while operating margin shifted from 0.7% to -1.9%. Net income was -$55.8M in FY2025, narrowing from -$164.9M in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $613.8M with an operating margin of -2.3%, supported by quarterly revenue growth of 12.0%.

As of June 30, 2026, Azenta held $325.8M in cash and short-term investments alongside total debt of $54.0M, resulting in net cash of $271.8M. Liquidity is supported by a current ratio of 2.50, while total assets of $1.88B and shareholders' equity of $1.51B yield a debt-to-equity ratio of 0.04. In FY2025, operating cash flow generated $72.2M, funding capital expenditures of $33.9M and resulting in free cash flow of $38.3M. Over the trailing 5-year period, the share count was reduced by 39.5%.

Azenta trades at a forward P/E of 29.1x, above the 17.3x median of its US-listed Healthcare peers. Its enterprise value of $1.22B and market cap of $1.49B translate to an EV-to-EBITDA of 37.1x, higher than the peer median of 12.0x, though its price-to-sales ratio of 2.4x sits below the peer median of 4.1x. Over the past year, AZTA gained 8.2%, trailing the S&P 500 return of 16.8%. Over 5 years, the stock fell 67.0%, compared to an 83.0% gain for the S&P 500.

Analyst ratings stand at 2 Strong Buy, 1 Buy, and 3 Hold recommendations. The mean price target of $39.00 indicates upside of 14.4% compared to the last close of $34.09. For the fiscal year ending September 30, 2026, consensus estimates project revenue of $614.9M and EPS of $0.32, reflecting an estimated EPS decline of 36.9%. For the following fiscal year, 4 analysts project revenue of $638.3M and EPS of $0.55. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 20, 2026.

This page is an AI-written research summary of Azenta, Inc. (AZTA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AZTA income statement, AZTA balance sheet, AZTA key metrics, AZTA analyst forecast, AZTA chart. See the AZTA stock overview for the latest quote and news.